Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Current Deferred Revenue (2016 - 2025)

Arrowhead Pharmaceuticals' Current Deferred Revenue history spans 14 years, with the latest figure at $111.9 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue changed N/A year-over-year to $111.9 million; the TTM value through Dec 2025 reached $111.9 million, changed N/A, while the annual FY2025 figure was $2.4 million, N/A changed from the prior year.
  • Current Deferred Revenue reached $111.9 million in Q4 2025 per ARWR's latest filing, up from $2.4 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $150.9 million in Q2 2021 to a low of $866000.0 in Q3 2023.
  • Average Current Deferred Revenue over 4 years is $71.1 million, with a median of $74.1 million recorded in 2022.
  • Peak YoY movement for Current Deferred Revenue: soared 1511.09% in 2021, then plummeted 98.83% in 2023.
  • A 4-year view of Current Deferred Revenue shows it stood at $108.7 million in 2021, then crashed by 39.0% to $66.3 million in 2022, then crashed by 98.69% to $866000.0 in 2023, then skyrocketed by 12825.29% to $111.9 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Current Deferred Revenue are $111.9 million (Q4 2025), $2.4 million (Q3 2025), and $23.0 million (Q2 2025).